Metastatic Colorectal Cancers Terminated Phase 2 Trials for Cetuximab (DB00002)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01522612Colorectal Cancer (CRC) Cetuximab Elderly FrailTreatment
NCT02316496Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II StudyTreatment
NCT01925274A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal CancerTreatment
NCT00531115Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.Treatment
NCT01718808Cetuximab for Elderly Patients With mCRCTreatment
NCT01858662Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT TumorsTreatment